


Indonesian. J. Pharm.
Volume 30 Issue 2 (2019)
April-June



ISSN : 2338-9427
Formerly ISSN : 0126-1037

Indonesian Journal of Pharmacy (*Indonesian J. Pharm.*)



Accredited by RISTEKDIKTI No 30/EKPT/2018

Faculty of Pharmacy
Universitas Gadjah Mada



Indonesian Journal of Pharmacy



[Home](#)
[About](#)
[Login](#)
[Register](#)
[Search](#)
[Current](#)
[Archives](#)
[Announcements](#)
[Indexing & Abstracting](#)
[Journal History](#)
[Contact](#)

Home > **Archives**

Archives

2019

Vol 30 No 2, 2019

Vol 30 No 1, 2019

2018



Vol 29 No 4, 2018



Vol 29 No 3, 2018



Vol 29 No 2, 2018



Vol 29 No 1, 2018

2017



Vol 28 No 4, 2017



Vol 28 No 3, 2017

[Focus & Scope](#)

[Author Guideline](#)

[Author Fees](#)

[Online Submission](#)

[Editorial Board](#)

[Peer Reviewer](#)

[Subscription Form](#)

[Screening for Plagiarism](#)

[Visitor Statistics](#)

This journal has been published by faculty of pharmacy Universitas Gadjah Mada in collaboration with IAI



CITATION ANALYSIS

[▶ SCOPUS](#)

[▶ GOOGLE SCOLAR](#)

TEMPLATE



TOOLS



NOTIFICATIONS

[▶ View](#)

[▶ Subscribe](#)

USER

Username

Indonesian Journal of Pharmacy



Home About Login Register Search Current Archives Announcements Indexing & Abstracting Journal History Contact

Home > Archives > Vol 30 No 2, 2019

Vol 30 No 2, 2019

Table of Contents

Articles

Citalopram and Tianeptine: Pharmacological Interventions in alcohol withdrawal-induced negative mood states and serotonin insufficiency in Albino Wistar male rats

Iffat Ara Amjad, Samina Bano Abdul Rub

DOI:10.14499/indonesianjpharm30iss2pp75-83 |Abstract view:75|PDF download:32

Synthesis and in Silico Studies of a Benzenesulfonyl Curcumin Analogue as a New Anti Dengue Virus Type 2 (DEN2) NS2B/NS3

Ihsan Ikhtiarudin

DOI:10.14499/indonesianjpharm30iss2pp84-90 |Abstract view:273|PDF download:61

Pharmacokinetics Interaction and Biodistribution of 5 Fluorouracil with Radiopharmaceuticals ^{99m}Tc Glutathione for Cancer Diagnostic in Mice Cancer Model

Ahmad Kurniawan, Teguh Hafidz Ambar Wibawa, Isti Daruwati, Iswahyudi Iswahyudi

DOI:10.14499/indonesianjpharm30iss2pp91-97 |Abstract view:121|PDF download:39

Effect of Platelet-rich Plasma on Caspase-3 and IGF-1 mRNA expression in the diabetic rat testis

Evi Istiqamah, Dicky Moch. Rizal, Ika Puspitasari

DOI:10.14499/indonesianjpharm30iss2pp98-104 |Abstract view:173|PDF download:24

Formulation, Characterization and Stability of Ibuprofen-Loaded Self-Nano Emulsifying Drug Delivery System (SNEEDS)

Yandi Syukri, Hannie Fitriani, Herianto Pandapotan, Bambang Hernawan Nugroho

DOI:10.14499/indonesianjpharm30iss2pp105-113 |Abstract view:209|PDF download:43

Hepatoprotective effects of Curcumin-Mesoporous Silica Nanoparticles on CCl₄ -induced Hepatotoxicity Wistar rats

Lannie Hadisoewignyo, Ivonne Soeliono, Sandy Budi Hartono, Eka Pramhyta Hestianah, Sri Rahayu Mahanani

DOI:10.14499/indonesianjpharm30iss2pp114-121 |Abstract view:134|PDF download:41

The Effect of Thionamide to TRH, TSH, IL-4, T-REG, and Anti-TPO in Graves' Disease

Eva Decroli, Dwitya Elvira, Dinda Aprilia

DOI:10.14499/indonesianjpharm30iss2pp122-127 |Abstract view:262|PDF download:61

Effect of Atorvastatin Treatment on Vascular Atherogenic Factors (Lipid Profiles and VCAM-1) in Patient Diabetes with Dyslipidemia

Asri Wido Mukti

DOI:10.14499/indonesianjpharm30iss2pp128-132 |Abstract view:251|PDF download:65

Evaluation of Pain Scale Decrease and Adverse Effects of Ketorolac Injections: An Observational Study in Patients with Postoperative Pain

Mawardi Ihsan, Fivy Kurniawati, Husna Khoirunnisa, Belladonna Chairini

DOI:10.14499/indonesianjpharm30iss2pp133-140 |Abstract view:152|PDF download:26

Immunomodulatory Activity of Yogurt Fortified with Honey and Rosella (*Hibiscus sabdariffa* L.) on Reactive Oxygen Intermediate (ROI) and Nitric Oxide (NO) Secretion

Nurkhasanah Mahfudh, Rina Novitasari

DOI:10.14499/indonesianjpharm30iss2pp141-146 |Abstract view:145|PDF download:24

Focus & Scope

Author Guideline

Author Fees

Online Submission

Editorial Board

Peer Reviewer

Subscription Form

Screening for Plagiarism

Visitor Statistics

This journal has been published by faculty of pharmacy Universitas Gadjah Mada in collaboration with IAI



CITATION ANALYSIS

► SCOPUS

► GOOGLE SCOLAR

TEMPLATE



TOOLS



NOTIFICATIONS

► View

► Subscribe

USER

Username

Effect of Atorvastatin Treatment on Vascular Atherogenic Factors (Lipid Profiles and VCAM-1) in Patient Diabetes with Dyslipidemia

Asri Wido Mukti¹, Budi Suprapti¹, and Sony Wibisono²

1. Magister of Clinical Pharmacy, Universitas Airlangga, Surabaya, Indonesia

2. Division Endocrinology and Metabolism - Department of Internal Medicine, Dr. Soetomo Teaching Hospital School of Medicine Airlangga University

Info Article

Submitted: 23-04-2018

Revised: 18-03-2019

Accepted: 09-04-2019

*Corresponding author
Asri Wido Mukti

Email
ninoasri@gmail.com

ABSTRACT

To analyze effectiveness of atorvastatin 20mg on lipid profiles and adhesion molecule VCAM-1 in patient with diabetes dyslipidemia. An observational prospective cohort study was conducted from November 2016 to March 2017. Patients who fulfilled the inclusion criteria were taken twice for their lipid profiles and VCAM-1 measurements (before initiation of study and after 6 weeks treatment of atorvastatin 20mg). There were 13 patients who met the inclusion criteria. The results of 13 patients showed that after 6 weeks of atorvastatin therapy, there was a 28% decrease in total cholesterol ($t_0=223.77\pm49.69$, $t_1=160.92\pm24.69$), 39% LDL decrease ($t_0=152.59\pm44.25$, $t_1=93\pm21.44$), a decrease in TG 38.6% ($t_0=200.85\pm101.53$, $t_1=123.30\pm62.77$) and a statistically significant decrease in VCAM-1 7.47% ($t_0=729.59\pm208.06$, $t_1=675.06\pm182.88$). The results of the correlation test between total cholesterol and VCAM-1 ($p=0.185$, $r=0.268$), LDL and VCAM-1 ($p=0.127$, $r=0.307$), TG and VCAM-1 ($p=0.198$, $r=0.261$) showed no correlation. Based on the results of the study, it can be concluded that atorvastatin therapy can provide improvements in atherogenic factors such as decreased lipid profile and VCAM-1, and there was no correlation between lipid profile and VCAM-1 in type 2 DM patients with dyslipidemia.

Keywords : Atorvastatin, Adhesion molecules, Diabetes mellitus, , dyslipidemia, VCAM-1.

INTRODUCTION

Diabetes mellitus (DM) is a metabolic disorder disease characterized by hyperglycemia (Triplitt *et al.*, 2014). The most common lipid pattern in people with type 2 diabetes consists of hypertriglyceridemia (hyper-TG), low high-density lipoprotein cholesterol (HDL-C), and relatively normal plasma concentrations of low-density lipoprotein cholesterol (LDL-C) (Hegele *et al.*, 2013). The condition of hyperglycemia and increased free fatty acids can cause endothelial damage, endothelial become more permeable, presence of reactive oxygen species (ROS), and increase adhesion molecules (George and Lyon, 2010). One of the adhesion molecules which has increased is VCAM-1. VCAM-1 is a member of the protein of immunoglobulin superfamily which is the framework for the migration of leukocytes to subendothelial space. If this leukocyte migration

not prevented will cause monocytes to mature into macrophages and form foam cell and fatty streak that will cause atherosclerosis (Wang and Huo, 2010).

Levels of soluble adhesion molecules have been shown to correlate with various cardiovascular risk factors including hypercholesterolemia and or hypertriglyceride, decreased HDL, hypertension, DM, and smoking. In two prospective studies of patients with type 2 diabetes, VCAM-1 became a strong predictor of cardiovascular mortality. VCAM-1 levels are also significantly associated with intima-media thickness, an index of early atherosclerotic (Wang and Huo, 2010).

Atorvastatin is a class of lipid-lowering agent, HMG CoA reductase inhibitor. HMG CoA is a precursor of mevalonate formation which is a synthesis of cholesterol (Malloy and Kane, 2012).

Atorvastatin also has a pleiotropic effect that can inhibit inflammation by inhibition of leukocytes by decreasing the expression of adhesion molecules, therefore the aim of this study was to analyze the effect of atorvastatin on lipid profile and pleiotropic effects as inhibition of inflammation.

MATERIAL AND METHODS

This study conducted a prospective observational design from November 2016 to March 2017 was approved by Ethics Committee of the the faculty of Medicine Airlangga University Surabaya. We included patients aged 35-79 years who were diagnosed with diabetic dyslipidemia, HbA1c 8-13%, lipid profiles during initiation of LDL therapy >100mg/dL and / or TG>150 mg/dL, free or at least 2-3 weeks after acute inflammation, and have not received atorvastatin therapy previously. Patients with elevated liver function tests (>3x normal values), patients with severe renal failure, patients with nephrotic syndrome with dyslipidemia, and patients taking progestin hormones, corticosteroids, and antiretroviral drugs (protease inhibitor class) were excluded from the study. Blood measurements were performed on lipid profiles (total cholesterol, LDL, and TG) and VCAM-1 before therapy of atorvastatin 20mg and after 6 weeks therapy. VCAM-1 were measured with ELISA method.

Analysis data started with normality test with Saphiro Wilk test. A comparative hypothesis test was performed to determined the differences of lipid profiles and VCAM-1 before therapy (t_0) and after therapy (t_1) with paired sample T-test and Wilcoxon test. In addition, a correlation test was performed to determine the correlation between lipid profile and VCAM-1 by using spearman correlation test.

RESULTS AND DISCUSSION

The number of male and female patients is almost equal with the most age range in the middle age range (46-59 years) (Table I). Based on research conducted by Mihardja et al in Indonesia also shows that the prevalence of DM increases with age with the highest age range 45-55 years (Mihardja *et al.*, 2014). HbA1c levels indicate uncontrolled sugar ranges (8-13%) and most patients are overweight (BMI 25-18kg/m²). Overweight and obesity are the most potent risk factors for DM (WHO, 2016). Three patients had comorbidities of hypertension and two patients with CHD. In a study conducted by Lastra (*et al.*) also found that hypertension was found in more

than 50% of patients with DM and contributed significantly to micro and macrovascular complications in DM. The risk factor for cardiovascular disease is 4 times higher in DM patients with hypertension (Lastra *et al.*, 2014).

The NCEP-ATP III guidelines divided LDL and TG levels within the range that can be used as indicative references when lipid-lowering therapy may be given. When TG levels are within a borderline high range, LDL-C is the main therapeutic target. Similarly, when TG levels are in the high range, LDL-C is still a major therapeutic target. Add lipid-lowering drugs such as fibrates to help reduce them. Individuals with very high TG levels (>500mg/dL) are at risk for acute pancreatitis, therefore the primary target is the reduction of TG first with a low-fat diet, weight management and physical activity, and the use of fibrates or nicotinic acid. If TG levels reach <500 mg/dl then it can be replaced again with LDL-lowering therapy (NCEPATP III, 2002).

Most patients had total cholesterol data in the range of borderline high (200-239mg/dL) are 62% with an average of 223.77±49.69mg/dL, LDL in the borderline high range (130-159mg/dL) and high (160-189mg/dL) are 38% with an average of 152.59±44.25mg/dL, triglycerides in the optimal range (<150mg/dl) are 54% with mean 200.85±101.53mg/dL, the patient's HDL level was mostly at the level of >40mg/dL (69%) with an average of 44.21±9.97mg/dL. Diabetes with dyslipemia is usually characterized by three conditions: high triglyceride concentrations, low HDL concentrations, and high small dense LDL concentrations (Chehade *et al.*, 2013). The baseline HDL values of patients were different than in those where only 31% of patients had low HDL values (<40mg/dL) (Table II).

It was found that after 6 weeks of treatment, there was a significant decrease in lipid profile (cholesterol, LDL, and TG) and VCAM-1 levels ($p < 0,05$). These results are consistent with previous studies conducted by hogue *et al.*, suggesting that the administration of atorvastatin 20mg for 6 weeks potentially altering lipid profile and also reduce inflammation (lowering CRP levels), oxidation (lowering levels of ox-LDL), and monocyte adhesion (Lowering levels of sICAM-1, sVCAM-1, sEselectin) in DM patients with hypertriglyceride (Hogue *et al.*, 2008) (Table III).

Correlation test is conducted to know the relationship between lipid profile level and VCAM-1. VCAM-1 increase in DM patients has been reported in previous studies, which is related to the

Table I. Baseline characteristic of patients

Patient Characteristics		Total Patients (N=13)		$\bar{x} \pm SD$ (range)
		n	%	
Gender	Male	6	46%	-
	Female	7	54%	-
Age	36-45 years	1	8%	54.84±6.70
	46-59 years	10	77%	
	60-74 years	2	15%	
HbA1c	8-10 %	7	54%	10.75±1.68
	11-13 %	6	46%	
BMI	18.5-24.9 kg/m ²	5	38%	26.79±5.11
	25.0-29.0 kg/m ²	6	46%	
	>30 kg/m ²	2	16%	
Comorbidities	Hypertension	3	23%	-
	CHD	2	15%	-

Table II. Baseline profil lipid pasien (t₀)

Levels of Lipid Profile		t ₀		t ₁	
		n	%	n	%
Total Cholesterol	Desirable (<200mg/dL)	3	23%	12	92%
	Borderline High (200-239mg/dL)	8	62%	1	8%
	High (≥240mg/dL)	2	15%	-	-
	Optimal (<100mg/dL)	1	8%	9	69%
LDL	Near optimal (100-129 mg/dL)	1	8%	3	23%
	Borderline high (130-159 mg/dL)	5	38%	1	8%
	High (160-189mg/dL)	5	38%	-	-
	Very high (≥190mg/dL)	1	8%	-	-
TG	Optimal (<150mg/dL)	7	54%	10	77%
	Near optimal (150-129mg/dL)	-	-	-	-
	Borderline high (200-499mg/dL)	6	46%	3	23%
HDL	High (≥500mg/dL)	-	-	-	-
	<40mg/dL	4	31%	3	23%
	>40mg/dL	9	69%	10	77%

Table III. Average changes in lipid profile and VCAM-1

Lipid Profiles	Mean ± SD		P
	t ₀	t ₁	
Total Cholesterol	223.77±49.69 (165-369)	160.92±24.69 (126-205)	0.002
LDL	152.59±44.25 (79-266)	93±21.44 (60-136)	0.001
TG	200.85±101.53 (103-377)	123.30±62.77 (68-246)	0.016
VCAM-1	729.59±208.06	675.06±182.88	0.019

severity of atherosclerotic disease (Fasching *et al.*, 1996). The result of correlation analysis between serum lipid profile level with serum VCAM-1 level (Figure 1, 2 and 3) showed no significant correlation ($p > 0.05$). Another study from Hubel *et*

al found that VCAM-1 correlated with LDL ($r = 0.50$, $P < 0.03$), but did not show any association with other lipid components (Hubel *et al.*, 1998). While in the study in Indonesia showed only correlation in patients with type 2 diabetes showed a tendency of




Figure 1. Correlation between total cholesterol and VCAM-1




Figure 2. Correlation Between LDL and VCAM-1




Figure 3. Correlation Between Triglycerida and VCAM-1

elevated plasma VCAM-1 levels along with the increase of albuminuria (Wibisono *et al.*, 2012). The limitation of this study is the relatively small sample size (13 patients), and the variation of lipid profiles among patients is very large because it is influenced by many factor. This can cause statistical results that are not meaningful.

CONCLUSION

Atorvastatin therapy is able to improved atherogenic factors such as decreased lipid profile (total cholesterol, LDL, TG) and VCAM-1

inflammatory markers in DM patients with dyslipidemia, and no correlation between lipid profile (total cholesterol, LDL, TG) and VCAM -1.

ACKNOWLEDGEMENT

All of subjects are acknowledged for participating in this study. Sony Wibisono, DR. dr., SpPD, KEMD., FINASIM is acknowledgment for constructing comments in manuscript. The authors also thank you to members of Magister of Clinical Pharmacy, Airlangga University, Surabaya and private clinic of endocrine consultant in Surabaya.

REFERENCES

- Cehade JM., Gladysz M. and Mooradian AD., 2013. Dyslipidemia in Type 2 Diabetes : Prevalence, Pathophysiology, and Management. *Drugs* 73:327-339.
- Fasching P, Veitl M, Rohac M, *et al.*, 1996. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism* ;81:4313-17.
- George SJ., and Lyon C., 2010. Pathogenesis of Atherosclerosis, In : *Atherosclerosis Molecular and Cellular Mechanisms*. Weinheim : WILEY-VCH Verlag GmbH & Co. KGaA, pp-3-14.
- John MGB., Hegele RA., and Leiter LA., 2013. Dyslipidemia. *Canadian Journal of Diabetes* 37 : S110eS116.
- Hogue JC., Lamarche B., Tremblay AJ., Bergeron J., Gagné C. and Couture P. 2008. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. *Metabolism Clinical and Experimental* 57. 380 - 386.
- Hubel CA., Fiona L., Lisa W., Robin E. Gandley; and James M. Roberts, 1998. Small Low-Density Lipoproteins and Vascular Cell Adhesion Molecule-1 Are Increased in Association With Hyperlipidemia in Preeclampsia. *Metabolism*. 47, No 10(October),1998:pp 1281-1288.
- Lastra G., Syed S., Romaine LK., MD., and Camila M., James RS., 2014. Type 2 diabetes mellitus and hypertension: An update. *Endocrinology and Metabolism Clinics of North America* 2014 March ; 43(1): 103-122.
- Malloy MJ. and John PK., 2012. Agents Used in Hyperlipidemia In : *Basic & Clinical Pharmacology* 10th edition. USA : McGraw-Hill. pp. 625
- Laurentia M., Soetrisno U. and Sidartawan Soegondo, 2014. Prevalence and clinical profile of diabetes mellitus in productive aged urban Indonesians. *Journal of Diabetes Investigation* 2014; 5: 507-512.
- NCEP-expert-panel, third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, *Circulation* 106 (2002) 3143-3421 Ohtawa, M., Masuda, N., Akasaka, I., et al., Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells. *British Journal of Clinical Pharmacology*, 1999, 47:383-389.
- Triplitt CL., Repas T. and Alvarez C., 2014. Diabetes Mellitus, In : *Pharmacotherapy A Pathophysiologic Approach* 9th edition . USA : McGraw Hill. pp 643-647
- Huang W. and Yuqing ., 2010. Adhesion Molecules and Atherosclerosis, In : *Atherosclerosis Molecular and Cellular Mechanisms*. Weinheim : WILEY-VCH Verlag GmbH & Co. KGaA, pp 43-55
- Wibisono C., Fajar A., Tjokroprawiro A., Soetjahjo A., Pranoto A., Adi S. and Murtiwi S., 2012. Profil Albuminuria dan Kadar sVCAM-1 Pada Penderita Diabetes Melitus Tipe 2. *Jurnal Penyakit Dalam* Vol 13 Nomor 1 Januari. Hal 28-35.

Indonesian Journal of Pharmacy



Home About Login Register Search Current Archives Announcements Indexing & Abstracting Journal History Contact

Home > About the Journal > People

People

Reviewer

- Dr. Enade Perdana Istyastono, Faculty of Pharmacy, Universitas Sanata Dharma, Indonesia
- Dr. Susi Ari Kristina, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Taha Nazir, Intellectual Consortium of Drug Discovery & Technology Development Inc., 937 Northumberland Ave Saskatoon Saskatchewan S7L3W8 Canada., Canada
- Dr. Gunawan Pamudji Widodo, Faculty of Pharmacy Setia Budi University Surakarta Indonesia, Indonesia
- Dr. Agatha Budi Susiana, Faculty of Pharmacy, Universitas Sanata Dharma, Indonesia
- Dr. Endang Lukitaningsih, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Adam Hermawan, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Uttam Budhathoki, Department of Pharmacy, Kathmandu University, Nepal
- Prof. Dr. Ridwan Amirudin, Faculty of Public Health, Universitas Hasanuddin, Indonesia
- Dr. Ari Sudarmanto, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Dyah Aryani Perwitasari, Faculty of Pharmacy, Universitas Ahmad Dahlan,, Indonesia
- Dr. Arief Nurrochmad, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Prof. Dr. Shufeng Zhou, Department of Pharmaceutical Sciences, University of South Florida Tampa, United States
- Dr. Triana Hadna, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Abdul Wahab, Department of Pharmacy, Kohat University of Science and Technology (KUST), Pakistan
- Dr. Montarat Thavorncharoensap, Faculty of Pharmacy, Department of Pharmacy, Mahidol University, Thailand
- Dr. Mohammed Emamussalehin Choudhury, Department of Pharmacology, Bangladesh Agriculture University, Bangladesh
- Dr. Dipak D Gadade, Shri Bhagwan College of Pharmacy, CIDCO N6, Aurangabad, India
- Dr I Wayan Mudianta, Ganesha University of Education, Bali, Indonesia, Indonesia
- Dr. Muthi Ikawati, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
- Dr. Nining Sugihartini, Faculty of Pharmacy, Universitas Ahmad Dahlan, Indonesia

Indonesian J Pharm indexed by:



- Focus & Scope
- Author Guideline
- Author Fees
- Online Submission
- Editorial Board
- Peer Reviewer
- Subscription Form
- Screening for Plagiarism
- Visitor Statistics

This journal has been published by faculty of pharmacy Universitas Gadjah Mada in collaboration with IAI



CITATION ANALYSIS

- ▶ SCOPUS
- ▶ GOOGLE SCOLAR

TEMPLATE



TOOLS



NOTIFICATIONS

- ▶ View
- ▶ Subscribe

USER

Username

Indonesian Journal of Pharmacy



[Home](#)
[About](#)
[Login](#)
[Register](#)
[Search](#)
[Current](#)
[Archives](#)
[Announcements](#)
[Indexing & Abstracting](#)
[Journal History](#)
[Contact](#)

Home > About the Journal > **Editorial Team**

Editorial Team

Editor in Chief

Prof. Sugiyanto Sugiyanto, Universitas Gadjah Mada, Department of Pharmacology and Clinical Pharmacy, Indonesia

Editorial Board

Prof. Dr. Abdul Rohman, Department of Pharmaceutical Chemistry, Faculty of Pharmacy Universitas Gadjah Mada, Indonesia
 Prof. Dr. Shufeng Zhou, Department of Pharmaceutical Sciences, University of South Florida Tampa, United States
 Prof. Dr. Kazutaka Maeyama, Ehime University, Department of Pharmacology, Japan
 Prof. Dr. Masashi Kawaichi, Nara Institute of Science and Technology, Division of Gene Function in Animals, Japan
 Prof. Dr. Gunawan Indrayanto, Universitas Airlangga, Faculty of Pharmacy, Indonesia
 Prof. Dr. Veeresh P. Veerapur, Sree Siddaganga College of Pharmacy, Pharmaceutical Chemistry Department, India
 Prof. Dr. Agung Endro Nugroho, Universitas Gadjah Mada, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Indonesia
 Prof. Dr. Lee E. Kirsch, University of Iowa, Division of Pharmaceutics and Translational Therapeutics, United States
 Prof. Dr. Henk Timmerman, Vrije Universiteit Amsterdam, Division of Medicinal Chemistry, Netherlands
 Prof. Dr. Jeroen Kool, Vrije Universiteit Amsterdam, Division of BioAnalytical Chemistry, Netherlands
 Dr. Saikat Kumar Basu, University of Lethbridge, Department of Biological Sciences, Canada
 Dr. Joseph David Francis Tucci, La Trobe University, School of Pharmacy and Applied Science, Australia
 Dr. Chuda Chittasupho, Srinakharinwirot University, Department of Pharmaceutical Technology, Thailand
 Dr. Rina Kuswahyuning, Universitas Gadjah Mada, Faculty of Pharmacy, Department of Pharmaceutics, Indonesia
 Dr. Supang Khonde, University of Phayao, School of Pharmaceutical Sciences, Thailand
 Dr. Pudjono Pudjono, Universitas Gadjah Mada, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Indonesia
 Dr. Montarat Thavorncharoensap, Faculty of Pharmacy, Department of Pharmacy, Mahidol University, Thailand
 Dr. Karuna Shanker, Central Institute of Medicinal and Aromatic Plants India, Department of Analytical Chemistry, India
 Dr. Jun An, Sun Yat-Sen University, Department of Cardiothoracic Surgery, China
 Dr. Mohammed Emamussalehin Choudhury, Department of Pharmacology, Bangladesh Agriculture University, Bangladesh
 Dr. Abdul Wahab, Department of Pharmacy, Kohat University of Science and Technology (KUST), Pakistan
 Dr. Tony Hadibarata, Curtin University Sarawak Malaysia, Department of Environmental Engineering, Malaysia
 Dr. Shahin Gavanji, Department of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Isfahan, Isfahan, Iran, Islamic Republic of

Indonesian J Pharm indexed by:



indonesianjpharm.farmasi.ugm.ac.id/index.php/3/about/editorialTeam

[Focus & Scope](#)

[Author Guideline](#)

[Author Fees](#)

[Online Submission](#)

[Editorial Board](#)

[Peer Reviewer](#)

[Subscription Form](#)

[Screening for Plagiarism](#)

[Visitor Statistics](#)

This journal has been published by faculty of pharmacy Universitas Gadjah Mada in collaboration with IAI




CITATION ANALYSIS

- ▶ SCOPUS
- ▶ GOOGLE SCOLAR

TEMPLATE



TOOLS



NOTIFICATIONS

- ▶ View
- ▶ Subscribe

USER



Effect of Atorvastatin Treatment on Vascular Atherogenic Factors (Lipid Profiles and VCAM-1) in Patient Diabetes with Dyslipidemia

Asri Wido Mukti

Abstract

To analyze effectiveness of atorvastatin 20mg on lipid profiles and adhesion molecule VCAM-1 in patient with diabetes dyslipidemia. An observational prospective cohort study was conducted from November 2016 to March 2017. Patients who fulfilled the inclusion criteria were taken twice for their lipid profiles and VCAM-1 measurements (before initiation of study and after 6 weeks treatment of atorvastatin 20mg). There were 13 patients who met the inclusion criteria. The results of 13 patients showed that after 6 weeks of atorvastatin therapy, there was a 28% decrease in total cholesterol ($t_0=223.77\pm49.69$, $t_1=160.92\pm24.69$), 39% LDL decrease ($t_0=152.59\pm44.25$, $t_1=93\pm21.44$), a decrease in TG 38.6% ($t_0=200.85\pm101.53$, $t_1=123.30\pm62.77$) and a statistically significant decrease in VCAM-1 7.47% ($t_0=729.59\pm208.06$, $t_1=675.06\pm182.88$). The results of the correlation test between total cholesterol and VCAM-1 ($p=0.185$, $r=0.268$), LDL and VCAM-1 ($p=0.127$, $r=0.307$), TG and VCAM-1 ($p=0.198$, $r=0.261$) showed no correlation. Based on the results of the study, it can be concluded that atorvastatin therapy can provide improvements in atherogenic factors such as decreased lipid profile and VCAM-1, and there was no correlation between lipid profile and VCAM-1 in type 2 DM patients with dyslipidemia.

Keywords

Atorvastatin, Adhesion molecules, Diabetes mellitus, , dyslipidemia, VCAM-1.

Full Text:

[PDF](#)

References

- Cehade et al., 2013. Dyslipidemia in Type 2 Diabetes : Prevalence, Pathophysiology, and Management. *Drugs* 73:327-339.
- Fasching P, Veitl M, Rohac M, et al., 1996. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism* ;81:4313-17.
- George, Sarah Jane; Lyon, Cressida, 2010. Pathogenesis of Atherosclerosis, In : *Atherosclerosis Molecular and Cellular Mechanisms*. Weinheim : WILEY-VCH Verlag GmbH & Co. KGaA, pp-3-14.
- Hegele et al., 2013. Dyslipidemia. *Canadian Journal of Diabetes* 37 : S110eS116.
- Hogue, Jean-Charles; Benoit Lamarche; André J. Tremblay, et al., 2008. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. *Metabolism Clinical and Experimental* 57 (2008) 380 – 386.
- Hubel, Carl A; Fiona Lyall; Lisa Weissfeld; Robin E. Gandley; and James M. Roberts, 1998. Small Low-Density Lipoproteins and Vascular Cell Adhesion Molecule-1 Are Increased in Association With Hyperlipidemia in Preeclampsia. *Metabolism*, Vol47, No 10(October),1998:pp 1281-1288.
- Lastra, Guido; Sofia Syed, L; Romayne Kurukulasuriya et al., 2014. Type 2 diabetes mellitus and hypertension: An update. *Endocrinology and Metabolism Clinics of North America* 2014 March ; 43(1): 103-122.
- Malloy, Mary J. & John P. Kane, 2012. *Agents Used in Hyperlipidemia In : Basic & Clinical Pharmacology* 10th edition. USA : McGraw-Hill. pp. 625
- Mihardja, Laurentia; Uken Soetrisno; and Sidartawan Soegondo, 2014. Prevalence and clinical profile of diabetes mellitus in productive aged urban Indonesians. *Journal of Diabetes Investigation* 2014; 5: 507-512.
- NCEP-expert-panel, third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, *Circulation* 106 (2002) 3143-3421 Ohtawa, M., Masuda, N., Akasaka, I., et al., Cellular uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells. *British Journal of Clinical Pharmacology*, 1999, 47:383-389.

[Focus & Scope](#)

[Author Guideline](#)

[Author Fees](#)

[Online Submission](#)

[Editorial Board](#)

[Peer Reviewer](#)

[Subscription Form](#)

[Screening for Plagiarism](#)

[Visitor Statistics](#)

This journal has been published by faculty of pharmacy Universitas Gadjah Mada in collaboration with IAI



CITATION ANALYSIS

[▶ SCOPUS](#)

[▶ GOOGLE SCOLAR](#)

TEMPLATE



TOOLS



NOTIFICATIONS

[▶ View](#)

[▶ Subscribe](#)

USER

Username



Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

- Home
- Journal Rankings
- Country Rankings
- Viz Tools
- Help
- About Us



Indonesian Journal of Pharmacy

Country	Indonesia -
Subject Area and Category	Health Professions Pharmacy Medicine Pharmacology (medical) Pharmacology, Toxicology and Pharmaceutics Pharmaceutical Science
Publisher	Universitas Gadjah Mada - Faculty of Pharmacy
Publication type	Journals
ISSN	23389486, 23389427
Coverage	2016-2019

5

H Index


Scope The journal had been established in 1972, and online publication was begun in 2008. Since 2012, the journal has been published in English by Faculty of Pharmacy Universitas Gadjah Mada (UGM) Yogyakarta Indonesia in collaboration with IAI (Ikatan Apoteker Indonesia or Indonesian Pharmacist Association) and only receives manuscripts in English. Indonesian Journal of Pharmacy is Accredited by Directorate General of Higher Education. The journal includes various fields of pharmaceuticals sciences such as: -Pharmacology and Toxicology -Pharmacokinetics -Community and Clinical Pharmacy -Pharmaceutical Chemistry -Pharmaceutical Biology -Pharmaceutics -Pharmaceutical Technology -Biopharmaceutics -Pharmaceutical Microbiology and Biotechnology -Alternative medicines.

- [Homepage](#)
- [How to publish in this journal](#)
- [Contact](#)
- [Join the conversation about this journal](#)


Quartiles




Quartiles




SJR



Citations per document




Total Cites Self-Cites




- Cites / Doc. (4 years)
- Cites / Doc. (3 years)
- Cites / Doc. (2 years)

External Cites per Doc Cites per Doc



% International Collaboration



Citable documents Non-citable documents

Cited documents Uncited documents

100

100

Indonesian Journal of Pharmacy



Pharmaceutical Science

SJR 2019 0.14

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scima
```

N

Niar 2 months ago

Why this journal not yet assigned quartile ?

reply

SCImago Team



Melanie Ortiz 2 months ago

Dear Niar,

Thank you for contacting us. Our data come from Scopus, they annually send us an update of the data. This update is sent to us around April / May every year. Thus, the indicators for 2019 will be available in June 2020. Best Regards, SCImago Team

F

faridatulain 9 months ago

i like this jurnal

reply

SCImago Team



Melanie Ortiz 9 months ago

Dear user, thanks for your participation! Best Regards, SCImago Team